Provectus adds fifth center to Phase II melanoma trial
Sanjiv Agarwala will serve as principal investigator at the new center, located at St Luke’s Hospital & Health Network, in Bethlehem, Pennsylvania. Over the next several months, the
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
In the six week, international, randomized, double-blind, placebo controlled study, 316 patients with an established diagnosis of schizoaffective disorder, who were experiencing acute symptoms, received either 6mg/day or